Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000622679 | SCV000742930 | uncertain significance | Inborn genetic diseases | 2017-09-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005091815 | SCV005838911 | likely pathogenic | Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase | 2024-12-09 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 89 of the AHCY protein (p.Ala89Val). This variant is present in population databases (rs755222515, gnomAD 0.003%). This missense change has been observed in individual(s) with AHCY-related conditions and/or S-Adenosylhomocysteine hydrolase deficiency (PMID: 16736098, 28779239, 33072517). ClinVar contains an entry for this variant (Variation ID: 522065). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt AHCY protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects AHCY function (PMID: 28647132). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Yale Center for Mendelian Genomics, |
RCV000662291 | SCV000784619 | likely pathogenic | Rhabdomyolysis | 2017-08-05 | no assertion criteria provided | literature only |